Abstract

Aims: To develop an approach for the effective treatment of ovarian tumor, prevention of metastases and limitation of side effects. Materials & Methods: In order to combine chemotherapy with genotherapy, we constructed a nanoscale-based tumor-targeted system containing two anticancer drugs, two antisense oligonucleotides (suppressors of cellular resistance) and a ligand specific to receptors overexpressed in cancer cells. The system was tested in a mouse metastatic xenograft model using tumor isolates from patients with ovarian carcinoma. Results: Treatment with the proposed nanosystem decreased primary tumor, prevented intraperitoneal metastases and limited adverse side effects. Conclusions: The advantages of the proposed targeted complex treatment of primary aggressive ovarian tumor and prevention of metastases make the proposed approach promising for clinical applications.

Original languageEnglish (US)
Pages (from-to)185-197
Number of pages13
JournalNanomedicine
Volume7
Issue number2
DOIs
StatePublished - Feb 1 2012

Fingerprint

Gene therapy
Chemotherapy
Genetic Therapy
Tumors
Neoplasm Metastasis
Neoplasms
Nanosystems
Antisense Oligonucleotides
Oligonucleotides
Heterografts
Ligands
Cells
Therapeutics
Carcinoma
Drug Therapy
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Bioengineering
  • Materials Science(all)
  • Biomedical Engineering
  • Medicine (miscellaneous)

Keywords

  • LHRH receptor-specific targeting
  • antisense oligonucleotides targeted to MDR1 and BCL2 mRNA
  • cisplatin
  • doxorubicin
  • liposomes
  • multicomponent nanosystem
  • primary and metastatic ovarian cancer
  • suppression of drug resistance

Cite this

@article{629c3f59a88d4133ac1490763704a9fc,
title = "Two-in-one: Combined targeted chemo and gene therapy for tumor suppression and prevention of metastases",
abstract = "Aims: To develop an approach for the effective treatment of ovarian tumor, prevention of metastases and limitation of side effects. Materials & Methods: In order to combine chemotherapy with genotherapy, we constructed a nanoscale-based tumor-targeted system containing two anticancer drugs, two antisense oligonucleotides (suppressors of cellular resistance) and a ligand specific to receptors overexpressed in cancer cells. The system was tested in a mouse metastatic xenograft model using tumor isolates from patients with ovarian carcinoma. Results: Treatment with the proposed nanosystem decreased primary tumor, prevented intraperitoneal metastases and limited adverse side effects. Conclusions: The advantages of the proposed targeted complex treatment of primary aggressive ovarian tumor and prevention of metastases make the proposed approach promising for clinical applications.",
keywords = "LHRH receptor-specific targeting, antisense oligonucleotides targeted to MDR1 and BCL2 mRNA, cisplatin, doxorubicin, liposomes, multicomponent nanosystem, primary and metastatic ovarian cancer, suppression of drug resistance",
author = "Kenneth Reuhl and Lorna Rodriguez-Rust and Tamara Minko",
year = "2012",
month = "2",
day = "1",
doi = "https://doi.org/10.2217/nnm.11.131",
language = "English (US)",
volume = "7",
pages = "185--197",
journal = "Nanomedicine",
issn = "1743-5889",
publisher = "Future Medicine Ltd.",
number = "2",

}

TY - JOUR

T1 - Two-in-one

T2 - Combined targeted chemo and gene therapy for tumor suppression and prevention of metastases

AU - Reuhl, Kenneth

AU - Rodriguez-Rust, Lorna

AU - Minko, Tamara

PY - 2012/2/1

Y1 - 2012/2/1

N2 - Aims: To develop an approach for the effective treatment of ovarian tumor, prevention of metastases and limitation of side effects. Materials & Methods: In order to combine chemotherapy with genotherapy, we constructed a nanoscale-based tumor-targeted system containing two anticancer drugs, two antisense oligonucleotides (suppressors of cellular resistance) and a ligand specific to receptors overexpressed in cancer cells. The system was tested in a mouse metastatic xenograft model using tumor isolates from patients with ovarian carcinoma. Results: Treatment with the proposed nanosystem decreased primary tumor, prevented intraperitoneal metastases and limited adverse side effects. Conclusions: The advantages of the proposed targeted complex treatment of primary aggressive ovarian tumor and prevention of metastases make the proposed approach promising for clinical applications.

AB - Aims: To develop an approach for the effective treatment of ovarian tumor, prevention of metastases and limitation of side effects. Materials & Methods: In order to combine chemotherapy with genotherapy, we constructed a nanoscale-based tumor-targeted system containing two anticancer drugs, two antisense oligonucleotides (suppressors of cellular resistance) and a ligand specific to receptors overexpressed in cancer cells. The system was tested in a mouse metastatic xenograft model using tumor isolates from patients with ovarian carcinoma. Results: Treatment with the proposed nanosystem decreased primary tumor, prevented intraperitoneal metastases and limited adverse side effects. Conclusions: The advantages of the proposed targeted complex treatment of primary aggressive ovarian tumor and prevention of metastases make the proposed approach promising for clinical applications.

KW - LHRH receptor-specific targeting

KW - antisense oligonucleotides targeted to MDR1 and BCL2 mRNA

KW - cisplatin

KW - doxorubicin

KW - liposomes

KW - multicomponent nanosystem

KW - primary and metastatic ovarian cancer

KW - suppression of drug resistance

UR - http://www.scopus.com/inward/record.url?scp=84863164382&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863164382&partnerID=8YFLogxK

U2 - https://doi.org/10.2217/nnm.11.131

DO - https://doi.org/10.2217/nnm.11.131

M3 - Article

C2 - 22339132

VL - 7

SP - 185

EP - 197

JO - Nanomedicine

JF - Nanomedicine

SN - 1743-5889

IS - 2

ER -